PremiumThe FlyMorning Movers: Pharmaceuticals sink as impending tariffs seen coming Amgen price target raised to $330 from $328 at Morgan Stanley Amgen announces FDA approval of Uplizna PremiumThe FlyBMO says Eylea court decision ‘modest negative’ for Regeneron Appeals court upholds denial of Regeneron motion for injunction against Amgen Regeneron down 3% after appeals court decision in Amgen patent fight PremiumThe FlyBiotech Alert: Searches spiking for these stocks today Positive Outlook for Amgen’s Stock Driven by Promising Rocatinlimab Trial Results Amgen’s Rocatinlimab Faces Challenges in Atopic Dermatitis Market: Hold Rating Maintained 
